Top Century Therapeutics Executive Makes Bold New Move in Company Stock

New insider activity at Century Therapeutics ( (IPSC) ) has taken place on December 29, 2025.Claim 70% Off TipRanks This Holiday SeasonUnlock hedge fund-level data and powerful investing tools for smarter, sharper decisions Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential Century Therapeutics’ Chief Scientific Officer, Chad Cowan, has increased his stake in the company by purchasing 58,060 shares of its stock in a recent transaction. The total value of this buy comes to $48,770, signaling a notable show of confidence from a key executive in the firm’s future prospects. Recent Updates on IPSC stock Over the last 24 hours, coverage of Century Therapeutics (IPSC) has focused on governance and pipeline updates rather than major price swings, with the stock framed neutrally by analysts and AI-driven tools. Recent price targets have been shaped by a balance of positive and negative factors: on the positive side, analysts cite strong technical momentum at times, expanding revenue, and constructive corporate moves such as the expansion of the Board of Directors with experienced life-science and capital-markets executives, as well as progress in its Allo‑Evasion cell-therapy platform and key programs (CNTY‑101 in Phase 1/2 for autoimmune disease and CNTY‑813 in preclinical development for Type 1 diabetes). On the negative side, they point to ongoing operating losses, negative cash flow and earnings, and a challenging valuation profile, leading to cautious views despite the strategic focus on extending the cash runway beyond key 2027 milestones. The recent resignation of board member Carlo Rizzuto was flagged as non‑controversial and not tied to operational disagreements, so it has not been a primary driver of sentiment; instead, expectations for the stock continue to be anchored in the tension between promising clinical and corporate developments and persistent financial weakness, which together explain the tempered, neutral stance in price targets. Spark’s Take on IPSC Stock According to Spark, TipRanks’ AI Analyst, IPSC is a Neutral. Century Therapeutics’ stock score is driven by strong technical momentum and positive corporate developments. However, financial performance and valuation remain weak due to ongoing losses and negative cash flow. To see Spark’s full report on IPSC stock, click here. More about Century Therapeutics YTD Price Performance: 4.33% Average Trading Volume: 1,277,926 Technical Sentiment Signal: Sell Current Market Cap: $94.83M